Robert S. Warren

Bob focuses primarily on venture and growth opportunities to invest in private life sciences and technology companies.

Robert joined ID Fund after a career as a corporate attorney, operating executive, entrepreneur and CPA. Most recently, Mr. Warren served as COO and CFO at AZTherapies, Inc., an advanced clinical-stage biopharmaceutical company out of the Massachusetts General Hospital developing novel treatments for neurodegeneration. Mr. Warren is currently a director for Nanotomer Incorporated, which is developing oncology drug delivery technologies out of Brigham and Women’s Hospital targeting the lymphatic system, and a business advisor to PhageNova Bio (f/k/a AAVP Biosystems), a development stage gene delivery company out of MD Anderson.

Previously Mr. Warren was a corporate partner in the Life Sciences Practice Group at Foley Hoag LLP, an AMLAW 100 law firm headquartered in Boston. Mr. Warren has been lead counsel on dozens of M&A transactions, representing both strategic and private equity buyers and company sellers (examples include the sale of iQuum to Roche 2014, the sale of deCode Genetics to Amgen in 2013 and the sale of Authorize.net to CyberSource (Visa) in 2007). Mr. Warren has extensive experience counseling public and private companies on complex corporate transactions, including mergers and acquisitions, financing transactions (including public offerings, PIPEs and venture capital investments) and strategic relationships.

In the late 1990s Mr. Warren served as Controller for a software localization start-up sold in mid-2000. He is also a CPA.

Robert has been a guest lecturer and speaker at Harvard Business School and Northeastern Law School and frequently serves as a judge and mentor for business plan and start-up competitions.